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Background: Many patients who survive a myocardial infarction (MI) remain at risk of sudden cardiac death despite
revascularization and optimal medical treatment. We used the modified moving average (MMA) method to assess
the utility of T-wave alternans (TWA) and heart rate turbulence (HRT) as risk markers in MI patients with or without
diabetes mellitus (DM).
Methods: We prospectively enrolled 248 consecutive patients: 96 with MI (post-MI patients); 77 MI with DM (post-
MI +DM patients); 75 controls without cardiovascular disease (group control). Both TWA and HRT were measured
on ambulatory electrocardiograms (AECGs). HRT was assessed by two parameters ─ turbulence onset (TO) and
turbulence slope (TS). HRT was considered positive when both TO ≥0% and TS ≤2.5 ms/R-R interval were met. The
endpoint was cardiac mortality.
Results: TWA values differed significantly between MI and controls. Post-MI +DM patients had higher TWA values
than post-MI patients (58 ± 21 μV VS 52 ± 18 μV, P= 0.029). Impaired HRT--increased TO and decreased TS were
observed in MI patients with or without DM. During follow-up of 578 ± 146 days, cardiac death occurred in ten
patients and three of them suffered sudden cardiac death (SCD). Multivariate analysis determined that a HRT-
positive outcome [HR (95% CI): 5.01, 1.33–18.85; P= 0.017], as well as the combination of abnormal TWA (≥47 μV)
and positive HRT had significant association with the endpoint [HR (95% CI): 9.08, 2.21–37.2; P= 0.002)].
Conclusion: This study indicates that AECGs-based TWA and HRT can predict cardiac mortality in MI patients with
or without DM. Combined analysis TWA and HRT may be a convenient and useful method of identifying patients at
high risk for cardiovascular death.
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Numerous studies over the past decades have provided a
sound scientific basis for employing T-wave alternans
(TWA), monitored during exercise testing, pacing, daily
activities or from defibrillator electrogram as an index of
vulnerability to ventricular arrhythmias and sudden car-
diac death, as it represents an increased heterogeneity of* Correspondence: qigx2002@medmail.com.cn
1Department of Cardiology, The First Affiliated Hospital of China Medical
University, Shenyang 110001, China
Full list of author information is available at the end of the article
© 2012 Li-na et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orventricle repolarization on a beat-to-beat basis, and may
provide a substrate for reentry [1-6]. Currently, there are
both frequency domain- and time domain-based analysis
methods of determining TWA. Our study used a time
domain-based modified moving average (MMA) to
analyze TWA measured on ambulatory electrocardio-
grams (AECGs) [7,8].
Following a premature ventricular contraction, there is a
compensatory sinus pause, followed by sinus acceleration
that typically overshoots the baseline heart rate before
gradually decelerating back to baseline. This sequence ofd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(HRT). Abnormal findings for HRT are defined as TO ≥0%
and TS ≤2.5 ms/RR interval [9]. Specifically, blunted post-
premature ventricular contraction, sinus acceleration (less
negative TO), and reduced subsequent deceleration (lower
TS) have been introduced as an autonomic risk stratifica-
tion marker for cardiac events after MI or ischemic cardio-
myopathy [9-12].
As is well known, diabetes mellitus (DM) not only
causes coronary artery disease and cardiac neuropathy,
but also increases the risk of cardiac death in post-MI
patients. Numerous studies have since established defini-
tively that hyperglycemia is highly prevalent and that it
is associated with an increased risk of death and in-
hospital complications in patients with MI [13,14].
In our study, we prospectively assessed the utility of
TWA and HRT, measured from 24-hour AECGs, in
identifying the risk of cardiac mortality in post-MI
patients with or without DM.
Methods
Patient population
Between April 2009 and December 2010 we prospectively
enrolled 248 consecutive patients at the Department of
Cardiology, the First Affiliated Hospital of China Medical
University, 25 of them have been previously included in
our prior study [15]. The population included 96 with MI
(post-MI patients); 77 with MI with DM (post-MI+DM
patients); and 75 controls (group control). The control
group included patients with palpitations who underwent
various noninvasive tests, such as 12-lead standard resting
electrocardiogram (ECG), conventional echocardiographic
and treadmill exercise tests, but were proven negative for
organic heart disease. The patients had a 24-hour AECGs
1 to 3 weeks after hospitalization. Patients did not with-
hold the beta-blockers while testing TWA. Left ventricular
ejection fraction (LVEF) was assessed by echocardiog-
raphy. The diagnosis of MI was based on clinical course,
serum creatine kinase levels, and ECG findings of ST-
segment elevation. Diabetes mellitus was defined as a
morning-fasting glucose of ≥126 mg/dL and hemoglobin
A1c ≥6.5%, or use of antidiabetic medication. Written
informed consent was obtained from each patient before
enrollment. All study subjects underwent a full clinical
examination and history, and any concurrent diseases and
medications were recorded. Patients with atrial flutter or
fibrillation, a cardiac pacemaker, atrioventricular block or
bundle-branch block, frequent extrasystoles, and severe
hepatic or renal disease were excluded.
T-wave alternans
Analyses of modified moving average-based TWA were
performed using the MARS PC system (GE HealthcareInc, Milwaukee, WI, USA) running software version 7.03.
Investigators who analyzed TWA and HRT were blinded
to clinical characteristics and outcomes. TWA was ana-
lyzed from three channel records (V1; NASA,V3; CM3,V5;
CM5) using AECGs measured as the peak difference in
TWA amplitude between odd- and even-numbered beats
at maximum heart rates (<120 beats/min). The MARS PC
software identified periods of possible TWA using the
MMA algorithm, a time domain-based method that bifur-
cates the beat stream and generates separate moving-
average templates for odd versus even beats [7]. Average
values were updated by a weighting factor of one-eighth
difference between the ongoing average and the current
pair of beats. TWA magnitude was analyzed as a continu-
ous variable and determined for each 15 s of data. An add-
itional algorithm minimized the effects of noise and
artifacts, and noise limits of 20 μV were adopted in the
system configuration. We overread and verified reported
TWA values using the templates, which not only allow
verification of TWA level but also allow investigators to
discard TWA values contaminated by noise or artifact.
Manual editing was performed if the data were ineligible
due to noise or artifacts. The max TWA value was defined
as the highest TWA value in any channel. In our study,
TWA≥ 47 μV was considered positive, based on previous
reports [16].
Heart rate turbulence
HRT was measured automatically using an algorithm ap-
plied to 24-hour AECGs obtained using the MARS
Holter system (GE Healthcare Inc., Milwaukee, WI,
USA). HRT parameters included turbulence onset (TO)
and turbulence slope (TS), which were determined
according to a previously published method [9]. The two
phases of HRT are quantified by two numeric descrip-
tors, TO and TS. TO is calculated as: TO= 100* ((RR1 +
RR2) -(RR-2 +RR-1)) /(RR-2 +RR-1) where RR-2 and
RR-1 are the two RR intervals immediately preceding
the VPC coupling interval, and RR1 and RR2 are two RR
intervals immediately after the compensatory pause. TS
is defined as the maximum positive regression slope
assessed over any 5 consecutive sinus rhythm RR inter-
vals within the first 15 sinus rhythm RR intervals after
the VPC. HRT values are usually classified into three cat-
egories: HRT Category 0: both TO and TS are normal
(TO <0% and TS >2.5 ms/RR interval); HRT Category 1:
either TO or TS is abnormal; HRT Category 2: both TO
and TS are abnormal [17].
Follow-up and study endpoints
All patients were followed as outpatients at our institute.
Regular follow-up contact was obtained at a hospital
visit every 2 or 3 months. When patients did not visit
for more than 3 months, our medical staff conducted
Table 1 Characteristics of enrolled patients twa values
and HRT parameters
Post-MI Post-MI +DM Group control
(N = 96) (N= 77) (N= 75) P value
Male gender 61(63.5%) 48(62.3%) 46(61.3%) P = 0.96
Age(years) 65 ± 10 66 ± 8 62± 9 P = 0.65
Hypertension 42(43.6%) 36(46.8%) 31(41.3%) P = 0.79
Heart Rate(bpm) 70 ± 9 69± 8 71± 9 P = 0.72
Medical therapies
ACEI/ARB 75(78.1%)* 62(80.5%)* 10(13.3%) P < 0.05
β-blockers 74(77.1%) * 60(77.9%)* 8(9.4%) P < 0.05
Statins 81(84.4%) * 64(83.1%)* 11(14.6%) P < 0.05
Site of infarction
Anterior 33(34.4%) 25(32.5%) – P = 0.29
Lateral 29(30.2%) 27(35.1%) – P = 0.79
Inferior 34(35.4%) 25(32.5%) – P = 0.24
Coronary
intervention
72(75.0%) 56(72.7%)) _ P = 0.74
Coronary bypass
surgery
14(14.6%) 12(15.6%)) _ P = 0.69
LVEF (%) 46 ± 9* 45 ± 8* 59 ± 5 P < 0.05
TWA(μV) 52 ±18* 58 ± 21*† 37 ± 13 P < 0.05
TO(%) -0.71 ± 2.17* -1.03 ± 3.12* -2.43 ± 1.71 P < 0.05
TS(ms/RRI) 4.96 ± 4.75* 4.60 ± 4.71* 13.03 ± 4.84 P < 0.05
* Post-MI patients with or without diabetes vs group control,P< 0.05.† Post-MI
patients vs post-MI + DM patients, P< 0.05. ACEI/ARB, angiotensin-converting
enzyme inhibitor/angiotensin-receptor blocker; LVEF, left ventricular injection
fraction; TWA, T-wave alternans; HRT, heart rate turbulence; TO, turbulence
onset; TS, turbulence slope.
Figure 1 T-wave alternans values in the three groups: Highest
in post-MI +DM patients and lowest in group control. Significant
differences were observed within the groups by multiple comparisons.
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defined as cardiac mortality. In patients who died, the
causes were verified from the hospital, and from either
the primary physicians or those who had witnessed the
death. Patients who died of noncardiac causes such as
stroke and cancer were not included in the endpoint and
were excluded from analysis.
Statistical analysis
All analyses were carried out using SPSS software, version
12.0 (SPSS Inc., Chicago, IL, USA). Data are presented as
the mean± SD or n (%). The statistical significance of dif-
ferences between groups was determined by chi-square
tests for discrete variables and t-tests for continuous vari-
ables. For analysis of the association between the end-
points and the clinical factors, Multivariate models to
predict events for all patients were developed by using
Cox proportional hazards regression. This Cox model
included the following variables: age, sex, TWA, category
of HRT, the presence of DM, LVEF and interaction of
TWA and HRT. All reported P values are 2-tailed with an
alpha level of 0.05 indicating statistical significance. A
P value <0.05 was considered statistically significant.
Results
Patient characteristics
There were no significant differences among the three
groups in age, hypertension and laboratory data. The
LVEF differed significantly between controls and post-
MI with or without DM patients (P < 0.05). There were
no differences between post-MI and post-MI+DM patients
in the sites of infarction or the coronary revascularization
procedures (Table 1).
T-wave alternans
The highest TWA values were found, as expected, in the
post-MI +DM patients, while the lowest were found in
the group control. There were significant differences in
TWA values among the three groups (P < 0.05). The
TWA values in post-MI +DM patients was higher than
that in post-MI patients (P= 0.029) (Figure 1). A figure
illustrating TWA in the AECGs of one of the patients
(Figure 2).
Heart rate turbulence
The average values for TO and TS differed significantly
between group control and the other two groups
(Table 1). HRT Category 0 had the highest incidence in
the group control. HRT Category 2 was higher in the
post-MI patients (abnormal in 20 patients [20.8%]) than
in group control, while the highest incidence was in the
post-MI +DM patients (abnormal in 18 patients [23.4%])
(Table 2).Positive results of TWA and HRT
Post-MI patients with or without diabetes had a higher
association of positive results for both TWA (≥47 μV)
and HRT (TO ≥0% and TS ≤2.5 ms/RRI) compared with
the group control (P < 0.05) (Figure 3). ROC curves for
maximum TWA and cardiac death. Area under the
curve was 0.708 (P= 0.021) (Figure 4).
Figure 2 Superimposed MMA waveforms for the maximum TWA in V1 (70 μV) and the associated AECGs strip for a patient. The
patient suffered SCD after 12 months.
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During a mean follow-up period of 578 ± 146 days, ten
patients reached the cardiac mortality endpoint (four in
post-MI patients, six in post-MI +DM patients). It was
witnessed that three patients had SCD (two in post-MI
patients, one in post-MI +DM patients). There was no
difference between MI patients with or without DM who
reached the endpoint. Two patients suffered noncardiac
death (i.e., stroke, liver cancer) and were excluded
from analysis. Multivariate analysis determined that a
HRT-positive outcome [HR (95% CI): 5.01, 1.33- 18.85;
P= 0.017], as well as the combination of abnormal
TWA and positive HRT had significant association with
the endpoint [HR (95% CI): 9.08, 2.21-37.2; P= 0.002)]
(Table 3).Table 2 Distribution of HRT category in the three groups
Post-MI Post-MI +DM Group control P value
(N= 96) (N = 77) (N= 75)
Category 0 42* 32 * 63 P< 0.05.
Category 1 34* 27* 11 P< 0.05.
Category 2 20* 18* 1 P< 0.05.
* Post-MI or post-MI +DM patients vs group control, P< 0.05
HRT, heart rate turbulence.Discussion
Patients with a positive microvolt-level TWA and HRT
are characterized by an increased risk of ventricular
tachyarrhythmias and cardiac mortality. We observed
that TWA was elevated in patients following MI as our
prior study [15]. Our data showed that patients in post
MI with DM have higher TWA values than those with-
out DM. MI patients with or without DM had higher as-
sociation with positive results for TWA and HRT. AFigure 3 Positive Results of TWA (≥47 μV) and HRT (TO ≥0%
and TS ≤2.5 ms/RRI):Post-MI with or without DM patients had a
higher association of positive results for both TWA and HRT.
Figure 4 ROC curve for T WA magnitude and Cardiac mortality.
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normal TWA and positive HRT had significant associ-
ation with cardiac mortality during the follow-up period.
Our study found that TWA was elevated in patients
following MI, HRT parameters-TO and TS were signifi-
cantly impaired in MI patients. A HRT-positive out-
come, as well as the combination of abnormal TWA and
positive HRT had significant association with the end-
point. Recently, the Consensus Guideline about TWA by
International Society for Holter and Noninvasive Elec-
trocardiology concluded the utility of TWA [18]. To
date, over 100 studies enrolling a total of more than
12,000 patients support the predictive of TWA testing
(including the frequency-domain Spectral Method and
the time-domain Modified Moving Average method) for
cardiovascular mortality and SCD. The HRT evaluation
has thus been found appropriate in risk stratification
after acute myocardial infarction (AMI), risk prediction,
and monitoring of disease progression in heart failure, as
well as in several other pathologies [12]. It is worth men-
tioning that in the REFINE (Risk Estimation FollowingTable 3 Hazard ratios for the capacity of the variables to




DM (yes/no) 0.36 (0.09—1.39) 0.14
LVEF(<40%) 1.04 (0.95—1.13) 0.44
HRT (positive) 5.01 (1.33—18.85) 0.02
TWA (≥47 μV) 7.44 (0.82—67.59 ) 0.08
TWA+HRT (TWA≥ 47 μV +HRT positive) 9.08 (2.22—37.8) 0.002
CI: confidence intervals; DM, diabetes mellitus; LVEF, left ventricular injection
fraction; HRT, heart rate turbulence; TWA, T-wave alternans; TWA+HRT, TWA
combined with HRT.Infarction Noninvasive Evaluation) trial they investigated
the capacity of combined assessment of autonomic tone
and cardiac electrical substrate to predict the develop-
ment of serious outcomes after MI, and found that
patients with impaired HRT plus abnormal Holter TWA
at 10 to 14 weeks after MI were at higher risk for cardiac
death or cardiac arrest, death from any cause, and fatal
or nonfatal cardiac arrest [19].
Diabetes mellitus (DM) is a well-established risk factor
for ischemic heart disease. Insulin resistance is a precur-
sor and a characteristic feature of T2DM and it is also
associated with higher risk of cardiovascular diseases
[20,21]. Rodríguez-Colón et al. reported that among per-
sons with T2DM have more severe form of insulin re-
sistance, and the circadian mechanisms of cardiac
autonomic modulation are impaired [22]. Prognosis after
MI is worse in patients with DM as compared to
patients without DM [13]. Autonomic nervous dysfunc-
tion is the main complication of DM and associated with
an increased risk of mortality in patients with diabetes
and survivors of myocardial infarction [23]. In our prior
study, TWA was moderate correlated with heart rate
variability (HRV), and seemed to be associated with the
sympathetic component of the autonomic nervous sys-
tem [15]. Elevated R wave amplitudes, widening of QTc
intervals and decreased HRV in an electrocardiogram
(ECG) are early markers of diabetic autonomic neur-
opathy. The severity of diabetic autonomic neuropathy
has a direct relationship with mortality risk. VanHoose
et al. found that aerobic exercise training may attenuate
the ECG changes, included R wave amplitudes, QTc
intervals and HRV in the model of T2DM-Zucker Dia-
betic Fatty rat [24]. Nieminen et al. found a significant
increase in TWA among diabetics in the FINCAVAS
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consecutive patients [16]. The prevalence of DM was the
only parameter that differed among the groups with stat-
istical significance. Molon et al. have shown that in
patients with DM and no known cardiovascular disease,
abnormal TWA prevalence was a very common condi-
tion (approximately 25%) among people with T2DM
without manifest cardiovascular disease and was closely
correlated to glycemic control [25,26]. In multivariate
regression logistic analysis, HbA1c (OR= 13.6, 95%
CI =2.0-89.1) predicted abnormal TWA independent of
other potential confounders. Jouven et al. conducted a
population-based case–control study at the Group
Health Cooperative [27]. Cases (n = 2040) experienced
out-of-hospital cardiac arrest due to heart disease. These
investigators observed that a progressively higher risk of
SCD was associated with borderline diabetes (OR= 1.24,
95% CI = 0.98-1.57), diabetes without microvascular dis-
ease (OR= 1.73, 95% CI = 1.28-2.34), and diabetes with
microvascular disease (OR= 2.66, 95% CI = 1.84-3.85).
Bonapace et al. studied 50 consecutive, well contr-
olled T2DM outpatients without a history of ischemic
heart disease and with normal systolic function [28].
All patients underwent a complete echocardiographic
Doppler evaluation with spectral tissue Doppler analysis.
TWA analysis was performed noninvasively during sub-
maximal exercise. Multivariable logistic regression
analysis revealed that higher E/e0 ratio was the only in-
dependent correlate of abnormal TWA (OR=3.52, 95%
CI = 1.19-10.6) after controlling for glycemic control and
other potential confounders. They found that early dia-
stolic dysfunction is independently associated with TWA
abnormality in T2DM individuals with normal systolic
function. Hennersdorf et al. found that abnormal TWA
was found in 33% of patients with both hypertension
and left ventricular hypertrophy (LVH) [29]. Hakalahti
et al. investigated the possible association between
the beta-1 adrenergic receptor (b1AR) Arg389Gly
polymorphism (which plays a fundamental role in the
regulation of cardiovascular functions) and LVH among
non-diabetic and diabetic AMI survivors [30]. They
found that the b1AR Arg389 variant seem to confer
higher risk of developing LVH among non-diabetic
patients who have suffered AMI. But it does not exist
among diabetic AMI survivors. They hypothesized that
this negative finding is caused by the strong association
between DM and LVH, which may mask the presumably
weaker effect of the b1AR Arg389 variant on the left
ventricular structure.
Miwa et al. assessed the utility of HRT as a risk marker
in post-MI patients with and without DM [31]. They
prospectively enrolled 231 consecutive DM patients and
300 non-DM patients after acute MI. HRT was consid-
ered positive when both TO ≥0% and TS ≤2.5 ms/RRIcriteria were met. The endpoint was defined as cardiac
mortality. Forty-two of 222 patients (19%) were HRT
positive. During follow-up of 876 ± 424 days, 26 patients
(22%) reached the endpoint. HRT- positive outcome
had significant value with a hazard ratio of 3.5 (95%
CI = 1.4-8.8). Stein et al. investigated 481 hospitalized
patients (24% of whom had DM) after AMI with HF and
left ventricular dysfunction [32]. Over a 1-year follow-
up, 55 died, 49 of cardiovascular causes. The study
showed that abnormal HRT predicted cardiovascular
mortality in high-risk patients with AMI and left ven-
tricular dysfunction. Bauer et al. found a higher percent-
age of abnormal values for both HRT parameters in
patients with DM than without DM in a subgroup ana-
lysis [33]. Barthel et al. enrolled 1455 survivors of an a
AMI who were in sinus rhythm [17]. The primary end-
point was all-cause mortality. During a follow-up of
22 months, 70 patients died. These investigators showed
that the combined assessment of HRT, LVEF ≤ 30%,
age ≥ 65 years, and DM can predict the population at
high risk. Thus, abnormal HRT is associated with DM in
post-MI patients, and HRT can detect cardiac neur-
opathy due to DM. Balcioğlu et al. investigated the de-
tection of diabetic neuropathy in patients with T2DM
and no obvious heart disease by autonomic markers that
included HRT and HRV, and found that HRT was the
most powerful indicator of cardiac diabetic neuropathy
[34]. Thus, HRT might be more sensitive indicators of
cardiac autonomic abnormality in post-MI patients with
DM because these patients have disturbance of both
parasympathetic and sympathetic tone.
However, negative studies have also appeared. Martin
et al. performed a case–control cross-sectional study in
140 patients [35]. Patients performed a symptom-limited
Bruce protocol exercise test with assessment of TWA by
the spectral method. Logistic regression analysis in all
patients showed that abnormal TWA was not related to
prevalent DM (OR= 0.9, 95% CI =0.4–1.8). Jackson et al.
investigated the utility of TWA treadmill testing in an
unselected population of patients with HF and found
that half of patients with HF are eligible for TWA testing
and the most common result is an indeterminate test
[36]. It concluded that TWA treadmill testing is not
widely applicable in typical HF patients and is unlikely
to refine risk stratification for sudden death. Wijers et al.
summarized the main reason for indeterminate test of
TWA treadmill testing [37]. They reported that inability
to achieve the target heart rate is the main reason for an
indeterminate result of TWA testing. Therefore, it is
questionable whether TWA alone is able to be of
predictive value and for what patient population. But
they concluded that combine a number of invasive and
non-invasive electrophysiological risk markers (including
TWA and short-term variability) could be the solution.
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Because of the limited scope of our study, we did not in-
clude ventricular late potentials obtained from signal-
averaged electrocardiogram, baroreflex sensitivity, and
other electrocardiographic markers, all of which have been
shown to be significant predictors in other populations. It
is not known the value of these markers in predicting car-
diac death or arrhythmic events in this study population.
Conclusions
The results of this study indicated that patients with MI,
especially those complicated with diabetes, have higher
TWA values and abnormal HRT, and have a high risk of
life threatening ventricular arrhythmias and cardiac
death, possibly because of increased repolarization hetero-
geneity and abnormal autonomic function. Combined
analysis using MMA-based TWA and HRT may be a con-
venient and useful method of predicting patients at high
risk for arrhythmic events and cardiovascular death.Abbreviations
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